{"id":81954,"date":"2026-06-18T12:05:35","date_gmt":"2026-06-18T12:05:35","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/"},"modified":"2026-06-18T12:05:35","modified_gmt":"2026-06-18T12:05:35","slug":"cour-pharma-announces-closing-of-50-million-series-b","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/","title":{"rendered":"COUR Pharma Announces Closing of $50 Million Series B"},"content":{"rendered":"<div>\n<p><em>Round led by Lumira Ventures and Roche Venture Fund with new investment from Sanofi<\/em><\/p>\n<p>CHICAGO, June  18, 2026  (GLOBE NEWSWIRE) &#8212; COUR Pharma, a clinical-stage biotechnology company developing \ufb01rst-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today it has closed a $50 million Series B funding round led by existing investors Lumira Ventures and Roche Venture Fund with participation from new investor, Sanofi. Existing investors including Alpha Wave Ventures, Pfizer Ventures, Angelini Ventures, and T1D Fund: A Breakthrough T1D Venture also participated, demonstrating continued conviction in COUR&#8217;s tolerance platform.<\/p>\n<p>The proceeds will be used to support the clinical advancement of CNP-103, an investigational therapy developed using COUR\u2019s proprietary nanoparticle platform for antigen-specific immune tolerance. CNP-103 is being evaluated in an active Phase 2 randomized, double-blind, placebo-controlled trial (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yb6GFlIllCH_B8zfd9tbRemD_Pd7kMAnW5J_hytGpdowNDStsG53D3zVF1erNmyDWl6SE5Sz_wtVZCb2HN8NJALZ_I3HqYKRnWXU2pInPFU_xozEirGfIafuH9LQw3F7\" rel=\"nofollow\" target=\"_blank\" title=\"NCT06783309\">NCT06783309<\/a>) to assess its safety, tolerability, pharmacodynamics, and efficacy in adolescents and adults ages 12-35 who have been diagnosed with type 1 diabetes (T1D) within the last six months. CNP-103 encapsulates four recombinant proteins which can reprogram the inflammatory autoimmune response directed toward islet cell destruction. Notably, these proteins are believed to cover &gt;95% of known antigens driving T1D. By inducing tolerance to these proteins, COUR aims to prevent further islet cell destruction and maintain insulin production at a clinically important level while potentially reversing dysglycemia.<\/p>\n<p>\u201cNew technological innovations have transformed the management of type 1 diabetes, yet the standard of care remains focused on controlling blood glucose rather than addressing the underlying autoimmune disease,\u201d said Dannielle Appelhans, President and Chief Executive Officer of COUR Pharma. \u201cOur clinically validated antigen-specific immune tolerance platform has the potential to change the treatment paradigm for T1D through a disease-modifying approach that is designed to protect insulin-producing cells from immune-mediated damage. We are excited to continue building evidence for the potential of immune tolerance therapies across autoimmune diseases.\u201d<\/p>\n<p>With the prioritization of evaluating CNP-103 in T1D, COUR is seeking partners for the clinical development of CNP-104 in primary biliary cholangitis and CNP-106 in myasthenia gravis.<\/p>\n<p><strong>About COUR Pharma<\/strong><br \/>COUR Pharma is a clinical-stage biotechnology company developing first-in-class antigen-specific immune tolerance therapies for autoimmune diseases. COUR\u2019s therapies are developed using a proprietary antigen-specific immune tolerance nanoparticle platform. COUR nanoparticles encapsulate disease-specific antigens and have been designed with specific features to mimic the anti-inflammatory nature of apoptotic cells. COUR\u2019s nanoparticles work to address the complexity of autoimmunity at its source, reprogramming upstream pathways to induce tolerance toward specific, disease-relevant autoantigens. Data from multiple clinical and preclinical programs have demonstrated the ability of COUR\u2019s product candidates to induce antigen-specific immune tolerance, with the potential to treat a wide range of autoimmune diseases.<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CAwoe2nHIn982ESFhvMbElKa_dFx7g49tEMHr8aBuzHwGgQMk6aXarYoTrtbhNr0nQk80FXbHLbzWM8zzT8328-L5kMvN03PC3UnQP3yoT3MyDGL1f5aN2yfA0IQyOEWeHdfMg3ZB23wMj_5YUH5VJFxwPqSqEDaEg_ZXTLzact3G4-XqWgwXmtwJ8w17HKRgbUDaEtIznYXmgXia6wXlRYapuI9CQ0pxGwSRxao2ge6O1sOKM8HWi3FBbaHOKCxpeA33A_lyaxYfxnNZy4SrQ==\" rel=\"nofollow\" target=\"_blank\" title=\"www.courpharma.com\">www.courpharma.com<\/a>.<\/p>\n<p><strong>Contacts<\/strong><\/p>\n<p>For Investor Relations<br \/>Brian Bock, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cog7t1Hrzifv4QWMKGlpmxr-spLR6x38ktiHuyFVtdVlsOLJ_ejFP5RLR24oAFb43acFnwlEarnbg1lo9Jf33eqwTg2LBnfGhdUNB4k_yOaRPL7LmR2_q85gHv0Qs7wXC48a88caSihQKOR1D5RSP_BXsqo5HBO8n5c-mH8EbNakKHmL2FieigB_Y2rxgp8aUVSn1ADlbuaFsbYAEHki8CG-bgdf6Mz1nFDNPLgYgj_-91LC-l5xEMAALbOKGFmLdRemnWujqrQPPWZUDPxfGw==\" rel=\"nofollow\" target=\"_blank\" title=\"bbock@courpharma.com\">bbock@courpharma.com<\/a><\/p>\n<p>For Media<br \/>Andrew Mielach<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XppiDdufyc-dxi7P5HtFFxGSG5C65ydVs-zHzybUWSoIQanUKUDyF3O5fy_mJ-hr8p1YznO3nq2qLfXR0bBWOWPZ7fe9vMnEFVBAbF4vTgnKsNlKbeDOh4FglY4s8KsK\" rel=\"nofollow\" target=\"_blank\" title=\"amielach@lifescicomms.com\">amielach@lifescicomms.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGI4YTdmNmItYzlmZC00N2Q5LTgyMTctN2ZlYmUzMzYzY2U1LTUwMDExMzU0OC0yMDI2LTA2LTE4LWVu\/tiny\/COUR-Pharma.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Round led by Lumira Ventures and Roche Venture Fund with new investment from Sanofi CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) &#8212; COUR Pharma, a clinical-stage biotechnology company developing \ufb01rst-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today it has closed a $50 million Series B funding round led by existing investors Lumira Ventures and [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-81954","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-people"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>COUR Pharma Announces Closing of $50 Million Series B - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COUR Pharma Announces Closing of $50 Million Series B\" \/>\n<meta property=\"og:description\" content=\"Round led by Lumira Ventures and Roche Venture Fund with new investment from Sanofi CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) &#8212; COUR Pharma, a cli\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-18T12:05:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1074\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"COUR Pharma Announces Closing of $50 Million Series B\",\"datePublished\":\"2026-06-18T12:05:35+00:00\",\"dateModified\":\"2026-06-18T12:05:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/\"},\"wordCount\":471,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"People\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/\",\"name\":\"COUR Pharma Announces Closing of $50 Million Series B - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-06-18T12:05:35+00:00\",\"dateModified\":\"2026-06-18T12:05:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"COUR Pharma Announces Closing of $50 Million Series B\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"COUR Pharma Announces Closing of $50 Million Series B - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/","og_locale":"en_US","og_type":"article","og_title":"COUR Pharma Announces Closing of $50 Million Series B","og_description":"Round led by Lumira Ventures and Roche Venture Fund with new investment from Sanofi CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) &#8212; COUR Pharma, a cli","og_url":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-06-18T12:05:35+00:00","og_image":[{"width":1074,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"COUR Pharma Announces Closing of $50 Million Series B","datePublished":"2026-06-18T12:05:35+00:00","dateModified":"2026-06-18T12:05:35+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/"},"wordCount":471,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["People"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/","url":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/","name":"COUR Pharma Announces Closing of $50 Million Series B - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-06-18T12:05:35+00:00","dateModified":"2026-06-18T12:05:35+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/cour-pharma-announces-closing-of-50-million-series-b\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"COUR Pharma Announces Closing of $50 Million Series B"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/81954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=81954"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/81954\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=81954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=81954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=81954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}